TempraMed Signs Exclusive Distribution Agreement with SPORTORO for Croatia, Serbia and Bosnia and Herzegovina

TempraMed secures a US$550,000 distribution deal for Southeast Europe, pending SPORTORO's execution.

What the company is saying

TempraMed Technologies Ltd. is announcing a definitive exclusive distribution agreement between its subsidiary, TempraMed Israel Ltd., and SPORTORO d.o.o. for Croatia, Serbia, and Bosnia and Herzegovina. The company frames this as a strategic expansion into three Southeast European healthcare markets, emphasizing the agreement's 36-month term, annual minimum purchase targets of approximately US$550,000, and coverage of VIVI Cap™, VIVI Epi™, and VIVI Med™. Management highlights the scale of diabetes and obesity in the region, citing 406,341 registered diabetics in Croatia, 718,500 in Serbia, and 316,400 in Bosnia and Herzegovina, as well as a 29.5% obesity prevalence in Croatia. The announcement stresses that SPORTORO will fund market development, obtain regulatory approvals, and develop commercial activities, with exclusivity conditional on performance. CEO Ron Nagar positions the agreement as a measurable, structured entry into new markets, while noting that actual sales and market penetration remain forward-looking.

What the data suggests

The agreement is legally binding, effective October 19, 2026, and covers a 36-month exclusive distribution period for TempraMed's products in Croatia, Serbia, and Bosnia and Herzegovina. The deal sets annual minimum purchase targets totaling approximately US$550,000 over three years, assuming an all-VIVI Cap product mix at current pricing, but this figure is illustrative and not a guaranteed revenue commitment. The first-year operational plan requires an initial order to be placed and paid in full upon execution, with a follow-up order targeted within six months. SPORTORO is responsible for all regulatory approvals and market development costs. The cited diabetes and obesity statistics—406,341 diabetics in Croatia (2025), 718,500 in Serbia (2024), 316,400 in Bosnia (2024), and 29.5% obesity prevalence in Croatia (2022)—demonstrate potential market size but do not translate directly to addressable sales or committed product uptake. The agreement's exclusivity and renewals are contingent on SPORTORO meeting performance conditions, and no realized sales, shipment volumes, or profitability metrics are disclosed. The structure provides a framework for entry but leaves actual financial impact dependent on future execution.

Analysis

The announcement is upbeat, highlighting a signed exclusive distribution agreement with SPORTORO d.o.o. for three Southeast European countries. The agreement is definitive and includes measurable minimum purchase targets (US$550,000 over 36 months), with an initial order to be placed and paid upon execution, which is a realised milestone. However, most of the operational and financial benefits are forward-looking: actual sales, regulatory approvals, and market development are all contingent on SPORTORO's future actions and market uptake. The exclusivity and renewal are subject to performance, and the minimum targets are not guaranteed revenue. The use of large diabetes and obesity prevalence statistics inflates perceived market opportunity but does not equate to committed sales. No profitability, margin, or cash flow data are disclosed, and the agreement's value is based on assumptions (all-VIVI Cap mix, current pricing). The gap between narrative and evidence lies in projecting significant market potential and structured plans, while only the agreement signing and initial order are realised.

Risk flags

• ●Revenue realization is contingent on SPORTORO meeting annual minimum purchase targets and successfully obtaining regulatory approvals in three countries. If SPORTORO fails to execute, actual sales could fall short of the illustrative US$550,000 figure, directly impacting TempraMed's revenue expectations.
• ●Exclusivity and agreement renewals are conditional on performance and other undisclosed criteria. If SPORTORO does not meet these conditions, TempraMed could lose exclusive access to these markets or face renegotiation, creating uncertainty around long-term market presence.
• ●SPORTORO has no established track record in medical device or healthcare product distribution, having historically operated in sporting goods and apparel. This lack of sector experience introduces execution risk in regulatory navigation, channel development, and sales conversion.
• ●The cited diabetes and obesity prevalence statistics inflate perceived market opportunity but do not represent the number of patients using injectable medications or the actual addressable market for TempraMed's products. This gap between potential and realistic uptake could lead to overestimated market expectations.
• ●All regulatory, market development, and sales activities are funded by the distributor, which may limit the pace or scale of market entry if SPORTORO underinvests or encounters unforeseen costs.

Bottom line

TempraMed's exclusive distribution agreement with SPORTORO opens a pathway to three Southeast European markets with a framework targeting US$550,000 in minimum purchases over three years. The deal is structured but not a guaranteed revenue stream; actual financial benefit will depend on SPORTORO's ability to obtain regulatory approvals, develop sales channels, and convert potential demand into real orders. The use of regional diabetes and obesity statistics highlights market potential but does not equate to committed sales or addressable market size. Execution risk is heightened by SPORTORO's lack of healthcare sector experience and the conditional nature of exclusivity. Investors should focus on evidence of realized orders, regulatory progress, and early sales traction to gauge whether this agreement translates into meaningful revenue. The most important takeaway is that while the agreement provides a credible entry strategy, its financial impact remains unproven until operational milestones are met.

Announcement summary

(CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) TempraMed Technologies Ltd. announced that its subsidiary, TempraMed Israel Ltd., has signed a definitive exclusive distribution agreement with SPORTORO d.o.o., a Croatian company headquartered in Osijek, for the commercialization of TempraMed products in Croatia, Serbia, and Bosnia and Herzegovina. The agreement, dated October 19, 2026, establishes an initial 36-month exclusive distribution framework covering VIVI Cap™, VIVI Epi™, and VIVI Med™. SPORTORO is responsible for developing commercial activities and obtaining all necessary country-specific governmental licenses and regulatory approvals at its own expense. The exclusivity of the agreement is subject to performance and other conditions as outlined in the agreement. The agreement sets annual minimum purchase targets valued at approximately US$550,000 over the 36-month initial term, assuming an all-VIVI Cap product mix at current pricing. First-year operational targets include an initial order to be placed and paid in full upon execution, with a subsequent order targeted within six months of the initial order. The agreement includes structured sales and marketing planning, distributor-funded market development, and conditional TempraMed launch support, with provisions for subsequent renewals subject to performance and mutual agreement. In Croatia, the Croatian Institute of Public Health reports 406,341 registered people with diabetes in 2025. The International Diabetes Federation estimates approximately 718,500 adults living with diabetes in Serbia and 316,400 in Bosnia and Herzegovina in 2024. The World Health Organization reports age-standardized adult obesity prevalence of 29.5% in Croatia in 2022. SPORTORO d.o.o. is a privately held Croatian company established in 2018 and led by director Mario Festetics de Tolna. Under the agreement, SPORTORO intends to extend its commercial activities into personal medication temperature protection and develop the necessary sales, marketing, and regulatory channels across Croatia, Serbia, and Bosnia and Herzegovina. Ron Nagar, Founder and Chief Executive Officer of TempraMed, stated that the agreement extends TempraMed's international distribution strategy into three additional Southeast European markets through a single commercial relationship. The agreement is structured with measurable purchase targets and a planned market-development program. TempraMed's commercial portfolio includes VIVI Cap™, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™.

Disagree with this article?